ZNG Medical
ZNG Medical
The global Therapeutic Apheresis Market is projected to grow significantly, reaching an estimated value of over USD 3.5 billion by 2028. This surge is driven by the increasing prevalence of autoimmune diseases, metabolic disorders, and hematological malignancies. Modern apheresis machines are no longer just blood filters; they are sophisticated AI-integrated platforms capable of multi-component separation.
Top-tier manufacturers are now focusing on "intelligent extracorporeal therapy." This includes automated anticoagulation management, real-time fluid balance monitoring, and remote diagnostic capabilities. As a leading exporter, understanding these technical nuances is what separates a standard supplier from a global industry leader.
Reliability is non-negotiable. Leading exporters must adhere to ISO 13485 and CE Marking standards. The industry landscape is dominated by companies that invest heavily in clinical validation, ensuring that every therapeutic plasma exchange (TPE) or cytapheresis procedure is executed with maximum safety.
The shift from central hospital labs to bedside treatment is accelerating. Manufacturers are developing compact therapeutic apheresis units that offer the same power as large-scale machines but with a smaller footprint, ideal for ICU settings.
The industry is moving toward highly selective columns that can target specific pathogens or antibodies without depleting healthy plasma components. This precision medicine approach reduces the need for expensive replacement fluids.
Advanced algorithms are now used to predict patient reactions and adjust flow rates dynamically. This reduces the burden on healthcare staff and minimizes the risk of human error during complex procedures like leukapheresis.
Zhejiang ZNG Medical, founded in 1996, stands as a leading medical device company at the forefront of injection and infusion technology. As a critical partner in the therapeutic apheresis ecosystem, we specialize in the high-precision needles and catheters that are essential for successful blood access and separation.
Through our ISO 9001 quality system and CE product certification, we provide the global market with secure and efficient products designed for the most demanding clinical environments.
Our Mission: We are committed to public health needs. By listening to customer feedback, we continuously improve our existing product line—ranging from fistula needles to microcannulas—to meet the evolving needs of therapeutic apheresis and other critical medical procedures.
Where precision medical devices meet clinical excellence.
In regions with high rates of kidney disease, our fistula needles and high-flow catheters are essential for maintaining stable vascular access during prolonged apheresis and dialysis sessions.
Therapeutic Plasma Exchange is a frontline treatment for Guillain-Barré syndrome and Myasthenia Gravis. Our sterile, hypoallergenic catheters ensure patient comfort during repeated procedures.
For stem cell collection and leukapheresis, the precision of the needle tip is paramount. ZNG Medical's specialized needle designs minimize vessel trauma and optimize flow rates.
From raw stainless steel to sterilized medical precision.
Producing Cannula
Injection Molding
Precise Assembling
Sterilized by EO
1. Detailed Requirement Analysis
2. Formal Technical Quotation
3. Free Prototype Samples
4. Purchase Order Verification
5. PI Confirmation & Deposit
6. Advanced Production Cycle
7. QA Photos & Inspection
8. Final Balance & Logistics
9. Global Shipment Booking
10. Real-time Delivery Tracking
11. Document Clearing Service
12. After-sales Technical Support
